| Title |
Pirfenidone treatment of idiopathic pulmonary fibrosis
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, February 2011
|
| DOI | 10.2147/tcrm.s12209 |
| Pubmed ID | |
| Authors |
Ye Gan, Erica L Herzog, Richard H Gomer |
| Abstract |
Idiopathic pulmonary fibrosis (IPF) is a discrete clinicopathologic entity defined by the presence of usual interstitial pneumonia on high-resolution CT scan and/or open lung biopsy and the absence of an alternate diagnosis or exposure explaining these findings. There are currently no FDA-approved therapies available to treat this disease, and the 5-year mortality is ∼80%. The pyridone derivative pirfenidone has been studied extensively as a possible therapeutic agent for use in this deadly disease. This review will present the unique clinical features and management issues encountered by physicians caring for IPF patients, including the poor response to conventional therapy. The biochemistry and preclinical efficacy of pirfenidone will be discussed along with a comprehensive review of the clinical efficacy, safety, and side effects and patient-centered foci such as quality of life and tolerability. It is hoped that this information will lend insight into the complex issues surrounding the use of pirfenidone in IPF and lead to further investigation of this agent as a possible therapy in this devastating disease. |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 55 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 25% |
| Student > Ph. D. Student | 8 | 14% |
| Student > Bachelor | 7 | 12% |
| Other | 7 | 12% |
| Researcher | 6 | 11% |
| Other | 8 | 14% |
| Unknown | 7 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 35% |
| Agricultural and Biological Sciences | 9 | 16% |
| Chemistry | 8 | 14% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Other | 6 | 11% |
| Unknown | 8 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2023.
All research outputs
#5,446,629
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#275
of 1,323 outputs
Outputs of similar age
#34,550
of 193,466 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#5
of 11 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 193,466 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.